Fierce Biotech1 min read
savePfizer taps Blackstone for up to $1.5B to pave path to GLP-1's obesity launch
Pfizer has secured up to $1.5 billion from Blackstone Life Sciences to fund development of its monthly GLP-1 receptor agonist.
Pfizer has secured up to $1.5 billion from Blackstone Life Sciences to fund development of its monthly GLP-1 receptor agonist.
comments(0)
5-min edit window · permanent after that